Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884552 | 0.85 | FFAR1 (0.48) | STK10SLKFFAR4FFAR1MEN1 | |
| SCHEMBL23875006 | 0.83 | SLC9A1 (0.37) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL23875007 | 0.82 | FFAR4 (0.41) | STK10SLKFFAR4FFAR1PTGDR2 | |
| SCHEMBL23875042 | 0.79 | SLK (0.39) | STK10SLKFFAR4FFAR1PDE4A | |
| SCHEMBL21884805 | 0.74 | STK10 (0.46) | STK10SLKFFAR4FFAR1MEN1 | |
| SCHEMBL21884553 | 0.72 | STK10 (0.38) | STK10SLKFFAR4FFAR1HPGD | |
| SCHEMBL23875057 | 0.72 | MRGPRX4 (0.36) | STK10SLKHPGDSMN1; SMN2NPC1 | |
| SCHEMBL23875026 | 0.70 | MGLL (0.42) | SMN1; SMN2NPC1RAB9APTGER1MRGPRX4 | |
| SCHEMBL21884486 | 0.70 | CCNT1 (0.40) | CDK9CCNT1 | |
| SCHEMBL23875066 | 0.67 | XDH (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | STK10 3618/4885SLK 4519/4885FFAR4 3825/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | STK10 2265/4885SLK 3760/4885FFAR4 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.